New perspectives and strategy research biomarkers for hepatocellular carcinoma

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 9, 2007, Pages 1169-1179

  Saffroy, Raphaël ^a   Pham, Patrick ^a   Reffas, Maĝmar ^a   Takka, Mohamed ^a   Lemoine, Antoinette ^a   Debuire, Brigitte ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

fetoprotein; Biological markers; Cirrhosis; Genomic; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; PROTEIN P16INK4A; PROTEIN P53; PROTHROMBIN; RETINOBLASTOMA PROTEIN; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR ALPHA;

CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ULTRASOUND;

ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; GLYCOSYLATION; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; TUMOR MARKERS, BIOLOGICAL;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 34548596823     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.262     Document Type: Review

References (124)

1. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211.
2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference-European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24.
4. Ganne-Carrié N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996;23:1112-8.
5. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999;29:1596-601.
6. Colombo M. Hepatocellular carcinoma in cirrhotics. Semin Liver Dis 1993;13:374-83.
7. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C for the Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999;31:133-41.
8. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1998;19:311-22.
9. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
11. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma. Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001;34:707-13.
12. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
13. Shimizu A, Ito K, Koike S, Fujita T, Shimizu K, Matsugana N. Cirrhosis or chronic hepatitis: evaluation of small (≤2 cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 2003;226:550-5.
14. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273-8.
15. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-38.
16. Sherman M. Alpha-fetoprotein: an obituary. J Hepatol 2001;34:603-5.
17. Trevisiani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbSAg and anti-HCV status. J Hepatol 2001;34:570-5.
18. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37:1114-21.
19. Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, et al. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005;11:6115-9.
20. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001;313:15-9.
21. Kudo M. Detection and curative treatment of early-stage hepatocellular carcinoma. Clin Gastroenterol Hepatol 2005;3:S144-8.
22. Giardina MG, Matarazzo M, Morante R, Lucariello A, Varriale A, Guardasole V, et al. Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer 1998;83:2468-74.
23. Cui R, He J, Zhang F, Wang B, Ding H, Li Y, et al. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gammaglutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer 2003;88:1878-82.
24. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Blake C, Ho SK. Structures of disease-specific serum alpha-fetoprotein isoforms. Br J Cancer 2000;83:1330-7.
25. Poon TC, Mok TS, Chan AT, Chan CM, Leong V, Tsui SH, et al. Quantification and utility of monosialylated α-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total α-fetoprotein. Clin Chem 2002;48:1021-7.
26. Tsai JF, Jeng JE, Chuang LY, You HL, Wang LY, Hsieh MY, et al. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma. Scand J Gastroenterol 2005;40:68-75.
27. Yoon SK, Lim NK, Ha SA, Park YG, Choi JY, Chung KW, et al. The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res 2004;64:5434-41.
28. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
29. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-73.
30. Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006;4:1528-36.
31. Han SJ, Yoo S, Choi SH, Hwang EH. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumor. Pediatr Surg Int 1997;12:599-602.
32. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki N, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336:1150-3.
33. Orsatti G, Theise ND, Thung SN, Paronetto F. DNA image cytometric analysis of macroregenerative nodules (adenomatous hyperplasia) of the liver: evidence in support of their preneoplastic nature. Hepatology 1993;17:621-7.
34. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002;181-182:43-7.
35. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004;24:77-88.
36. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127:S87-96.
37. Grisham JW. Molecular genetic alterations in primary hepatocellular neoplasms: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma. In: Coleman WB, Tsongalis GJ, editors. The molecular basis of human cancer. Totowa, NJ: Humana Press, 2001:269-346.
38. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000;32:970-9.
39. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001;61:4238-43.
40. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
41. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006;387:349-60.
42. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999;19:235-42.
43. Bourdon JC, D'errico A, Paterlini P, Grigioni W, May E, Debuire B. P53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 1995;108:1176-82.
44. Shiota G, Kishimoto Y, Suyama A, Okubo M, Katayama S, Harada K, et al. Prognostic significance of serum antip53 antibody in patients with hepatocellular carcinoma. J Hepatol 1997;27:661-8.
45. Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, et al. Clinical significance of circulating antip53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 1999;79:604-10.
46. Charuruks N, Tangkijvanich P, Voravud N, Chatsantikul R, Theamboonlers A, Poovorawan Y. Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. J Gastroenterol 2001;36:830-6.
47. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-51.
48. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, et al. Beta-Catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999;18:4044-6.
49. Terris B, Pineau P, Bregeaud L, Valla D, Belghiti J, Tiollais P, et al. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999;18:6583-88.
50. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157:763-70.
51. Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol 2000;31:558-65.
52. Wong CM, Fan ST, Ng IO. Beta-catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 2001;92:136-45.
53. Fujito T, Sasaki Y, Iwao K, Miyoshi Y, Tamada T, Ohigashi H, et al. Prognostic significance of beta-catenin nuclear expression in hepatocellular carcinoma. Hepatogastroenterology 2004;51:921-4.
54. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73.
55. Devereux TR, Anna CH, Foley JF, White CM, Sills RC, Barrett JC. Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene 1999;18:4726-33.
56. Renard CA, Fourel G, Bralet MP, Degott C, De La Coste A, Perret C, et al. Hepatocellular carcinoma in WHV/Nmyc2 transgenic mice: oncogenic mutations of betacatenin and synergistic effect of p53 null alleles. Oncogene 2000;19:2678-86.
57. Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001;193:95-101.
58. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-50.
59. Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21:4863-71.
60. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M, et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 1997;71:355-59.
61. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002;8:385-92.
62. Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2002;8:638-43.
63. Dawson S, Higashitsuji H, Wilkinson AJ, Fujita J, Mayer RJ. Gankyrin: a new oncoprotein and regulator of pRb and p53. Trends Cell Biol 2006;16:229-33.
64. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999;18:4879-83.
65. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001;84:1377-83.
66. Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004;41:1008-16.
67. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41:307-14.
68. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63.
69. Sheu JC, Lin YW, Chou HC, Huang GT, Lee HS, Lin YH, et al. Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan. Br J Cancer 1999;80:468-76.
70. Wang G, Zhao Y, Liu X, Wang L, Wu C, Zhang W, et al. Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes Cancer 2001;31:221-7.
71. Chang YC, Ho CL, Chen HH, Chang TT, Lai WW, Dai YC, et al. Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum. Br J Cancer 2002;87:1449-53.
72. Nishida N, Fukuda Y, Komeda T, Ito T, Nishimura T, Minata M, et al. Prognostic impact of multiple allelic losses on metastatic recurrence in hepatocellular carcinoma after curative resection. Oncology 2002;62:141-8.
73. Salvucci M, Lemoine A, Azoulay D, Sebagh M, Bismuth H, Reyns M, et al. Frequent microsatellite instability in post hepatitis B viral cirrhosis. Oncogene 1996;13:2681-5.
74. Salvucci M, Lemoine A, Saffroy R, Azoulay D, Lepere B, Gaillard S, et al. Microsatellite instability in European hepatocellular carcinoma. Oncogene 1999;18:181-7.
75. Karachristos A, Liloglou T, Field JK, Deligiorgi E, Kouskouni E, Spandidos DA. Microsatellite instability and p53 mutations in hepatocellular carcinoma. Mol Cell Biol Res Commun 1999;2:155-61.
76. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Microsatellite instability associated with hepatocarcinogenesis. J Hepatol 1999;31:529-36.
77. Kawai H, Suda T, Aoyagi Y, Isokawa O, Mita Y, Waguri N, et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 2000;31:1246-50.
78. Dore MP, Realdi G, Mura D, Onida A, Massarelli G, Dettori G, et al. Genomic instability in chronic viral hepatitis and hepatocellular carcinoma. Hum Pathol 2001;32:698-703.
79. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 1998;28:91-7.
80. Chiappini F, Gross-Goupil M, Saffroy R, Azoulay D, Emile JF, Veillhan LA, et al. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis 2004;25:541-7.
81. Lin YW, Sheu JC, Huang GT, Lee HS, Chen CH, Wang JT, et al. Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan. Eur J Cancer 1999;35:652-8.
82. Finkelstein SD, Marsh W, Demetris AJ, Swalsky PA, Sasatomi E, Bonham A, et al. Microdissection-based allelotyping discriminates de novo tumor from interhepatic spread in hepatocellular carcinoma. Hepatology 2003;37:871-9.
83. Terracciano L, Tornillo L. Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. Pathologica 2003;95:71-82.
84. Nishikawa M, Nishiguchi S, Shiomi S, Tamori A, Koh N, Takeda T, et al. Somatic mutation of mitochondrial DNA in cancerous and noncancerous liver tissue in individuals with hepatocellular carcinoma. Cancer Res 2001;61:1843-5.
85. Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D. Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res 2002;8:481-7.
86. Okochi O, Hibi K, Uemura T, Inoue S, Takeda S, Kaneko T, et al. Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res 2002;8:2875-8.
87. Lee HC, Li SH, Lin JC, Wu CC, Yeh DC, Wei YH. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res 2004;547:71-8.
88. Herath NI, Leggett BA, MacDonald GA. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol 2006;21:15-21.
89. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006;25:2537-45.
90. Lemmer ER, Friedman SL, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin Liver Dis 2006;26:373-84.
91. Lau WY, Lai PB, Leung MF, Leung BC, Wong N, Chen G, et al. Differential gene expression of hepatocellular carcinoma using cDNA microarray analysis Oncol Res 2000;12:59-69.
92. Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001;98:15089-94.
93. Tackels-Horne D, Goodman MD, Williams AJ, Wilson DJ, Eskandari T, Vogt L, et al. Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling. Cancer 2001;92:395-405.
94. Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001;33:832-40.
95. Graveel CR, Jatkoe T, Madore SJ, Holt AL, Farnham PJ. Expression profiling and identification of novel genes in hepatocellular carcinomas. Oncogene 2001;20:2704-12.
96. Wu CG, Salvay DM, Forgues M, Valerie K, Farnsworth J, Markin RS, et al. Distinctive gene expression profiles associated with Hepatitis B virus x protein. Oncogene 2001;28:3674-82.
97. Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, et al. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells 2002;14:382-7.
98. Iizuka N, Tamesa T, Sakamoto K, Miyamoto T, Hamamoto Y, Oka M. Different molecular pathways determining extrahepatic and intrahepatic recurrences of hepatocellular carcinoma. Oncol Rep 2006;16:1137-42.
99. Lee JS, Thorgeirsson SS. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 2002;35:1134-43.
100. Li Y, Tang R, Xu H, Qiu M, Chen Q, Chen J, et al. Discovery and analysis of hepatocellular carcinoma genes using cDNA microarrays. J Cancer Res Clin Oncol 2002;128:369-79.
101. Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, et al. Identification of discriminators of hepatoma by gene expression profiling using a minimal data set approach. Hepatology 2004;39:944-53.
102. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003;361:923-9.
103. Paradis V, Bieche I, Dargere D, Laurendeau I, Laurent C, Bioulac Sage P, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003;163:733-41.
104. Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, Ng IO, et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002;62:4711-21.
105. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004;130:497-513.
106. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006;27:251-9.
107. Chignard N, Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 2004;127:S120-5.
108. Steel LF, Shumpert D, Trotter M, Seeholzer SH, Evans AA, London WT, et al. A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 2003;3:601-9.
109. Ren N, Ye QH, Qin LX, Zhang BH, Liu YK, Tang ZY. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol 2006;12:3911-4.
110. Niu Q, Tang ZY, Qin LX, Ma ZC, Zhang LH. Loss of heterozygosity at D14S62 and D14S51 detected by a simple and non-radioactive method in plasma DNA is a potential marker of metastasis and recurrence after curative hepatic resection in hepatocellular carcinoma. Hepatogastroenterology 2003;53:1579-82.
111. Szymanska K, Lesi OA, Kirk GD, Sam O, Taniere P, Scoazec JY, et al. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. Int J Cancer 2004;110:374-9.
112. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59:71-3.
113. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000;9:3516-21.
114. Wong IH, Zhang J, Lai PB, Lau WY, Lo YM. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res 2003;9:1047-52.
115. Wang J, Qin Y, Li B, Sun Z, Yang B. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem 2006;39:344-8.
116. Lemoine A, Le Bricon T, Salvucci M, Azoulay D, Pham P, Raccuia J, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery. Ann Surg 1997;226:43-50.
117. Louha M, Nicolet J, Zylberberg H, Sabile A, Vons C, Vona G, et al. Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells. Hepatology 1999;29:879-82.
118. Witzigmann H, Geissler F, Benedix F, Thiery J, Uhlmann D, Tannapfel A, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. Surgery 2002;131:34-43.
119. Gross-Goupil M, Saffroy R, Azoulay D, Precetti S, Emile JF, Delvart V, et al. Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma. Ann Surg 2003;238:241-8.
120. Cillo U, Navaglia F, Vitale A, Molari A, Basso D, Bassanello M, et al. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clin Chim Acta 2004;347:129-38.
121. Kamiyama T, Takahashi M, Nakagawa T, Nakanishi K, Kamachi H, Suzuki T, et al. AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg 2006;244:451-63.
122. Miyamoto A, Fujiwara Y, Sakon M, Nagano H, Sugita Y, Kondo M, et al. micrometastases of hepatocellular carcinoma. Dig Dis Sci 2000;45:1376-82.
123. Mou DC, Cai SL, Peng JR, Wang Y, Chen HS, Pang XW, et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells. Br J Cancer 2002;86:110-6.
124. Yang SZ, Dong JH, Li K, Zhang Y, Zhu J. Detection of AFP mRNA and melanoma antigen gene-1 mRNA as markers of disseminated hepatocellular carcinoma cells in blood. Hepatobiliary Pancreat Dis Int 2005;4:227-33.